Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in childrenOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether gut microbiota diversity around allogeneic hematopoietic stem cell transplantation predicts survival and complications in children. Researchers profiled stool with 16S rRNA amplicon sequencing at two time points, before transplant and at neutrophil engraftment. They estimated diversity using the Shannon index and split patients into higher and lower diversity groups at the cohort median. A networking approach mapped the ecological structure of each community. Primary endpoint was overall survival. Secondary endpoints included relapse, acute graft-versus-host disease, transplant-related mortality, and bloodstream infections.
Who was studied?
The cohort was 90 pediatric allogeneic transplant recipients from five hospitals in Italy and Poland, contributing 180 stool samples. Each child had one sample before transplant and one at neutrophil engraftment. Children were transplanted for malignant and nonmalignant diseases. Samples were collected between 2013 and 2020. Diversity fell sharply from before transplant to engraftment. The median Shannon value used to stratify groups was 4.04 before transplant and 2.86 at engraftment. Diversity was lower in children aged 3 years or younger.
What were the most important findings?
Higher pretransplant diversity predicted better survival. Estimated overall survival was 88.9% (plus or minus 5.7%) in the higher diversity group versus 62.7% (plus or minus 8.2%) in the lower diversity group (P = .011). The higher diversity group had less grade 2 to 4 acute graft-versus-host disease (20.0% vs 44.4%, P = .017) and less grade 3 to 4 disease (2.2% vs 20.0%, P = .007). Higher diversity communities were enriched in short-chain fatty acid producers such as Ruminococcaceae, Oscillospiraceae, Blautia, Faecalibacterium, and Roseburia. Lower diversity communities were dominated by Enterococcaceae and Enterobacteriaceae, with keystone taxa Enterococcus, Escherichia-Shigella, and Enterobacter. Diversity at engraftment showed no significant link to outcomes.
What are the greatest implications of this study?
The findings suggest that the pretransplant window, rather than engraftment, may be the key period to protect the gut microbiota in children. This differs from adult data, where engraftment diversity predicts survival. A healthy, modular network of short-chain fatty acid producers appeared more protective than any single taxon. Longer antibiotic exposure before admission was associated with lower diversity. The authors propose early, personalized interventions from diagnosis onward. This is an observational multicenter study, so associations do not establish that raising diversity would improve survival.